FDA Issues Warning About Rare But Severe Reaction When Stopping Allergy Medications

FDA Issues Warning About Rare But Severe Reactions When Discontinuing Allergy Medications

In a recent announcement, the U.S. Food and Drug Administration (FDA) has issued a warning regarding a rare but severe reaction that can occur when individuals stop taking specific allergy medications such as Zyrtec or Xyzal. The agency has highlighted that individuals who discontinue these medicines after prolonged use may experience a serious itching sensation.

The uncomfortable side effect, known as “pruritus,” typically manifests within a few days of stopping medications like cetirizine (Zyrtec) or levocetirizine (Xyzal) following months or years of regular consumption. The FDA emphasized that patients had not experienced itching before initiating the medication. Reported cases of this reaction were uncommon but occasionally severe, requiring medical intervention due to widespread and intense itching.

The FDA disclosed that symptoms of itching may alleviate upon resuming the allergy medications. If individuals encounter severe itching after discontinuing their allergy pills, health officials urge them to promptly contact their healthcare providers for assistance and guidance.

According to the FDA, over 200 global cases of pruritus following the cessation of these medicines were identified between April 2017 and July 2023. Despite the sale of an estimated 60 million-plus packages of over-the-counter allergy medications in 2022, the FDA noted that occurrences of pruritus post-medication discontinuation are infrequent considering the widespread usage of these medications.

In response to these findings, the FDA is revising the prescribing information for certain allergy medications to incorporate a new warning about this potential risk. The agency has also requested manufacturers of the over-the-counter variants to include a warning on the Drug Facts Labels to inform consumers about the risk of severe itching upon discontinuation.

Following the FDA’s announcement, representatives from pharmaceutical companies producing Zyrtec and Xyzal provided limited information in response. A representative from Zyrtec informed PEOPLE that they did not possess additional details regarding the FDA warning. Similarly, a representative from Sanofi, the manufacturer of Xyzal, declined to comment over the phone and did not respond immediately to an email request for further information.

As the FDA continues to monitor and assess this situation, they aim to keep the public informed about any developments related to this rare but concerning side effect associated with discontinuing certain allergy medications. Individuals are encouraged to stay updated with reliable sources and seek medical advice if they experience severe itching after halting their allergy medication regimen.

With the FDA’s proactive approach in issuing warnings and updates on medication safety, it underscores the importance of being vigilant and informed about potential risks associated with commonly used medications. Awareness of such adverse reactions can empower individuals to make informed decisions about their healthcare and seek timely assistance when needed.